Dr Adam M Hill
Chief Executive Officer
Adam is a dual-qualified Clinician and Mechanical Engineer with a career built at the interface of industry, academia and health systems. Over the last two decades he has trained in surgery in the British Army; founded a successful applied research centre at Imperial College London; provided growth strategy and investment advice to global life science companies on behalf of the British Government; led the global medical function of a multinational, publicly-listed health IT company; and pivoted a Formula One team into a developer of health technology. Currently, Adam sits on the board of the ABHI as Vice Chair, is a Visiting Professor in Global Health Innovation at Imperial College London and a Non-Executive Director of Imperial College Health Partners and MyRecovery.ai.
Adam graduated from Imperial College London as a Medical Doctor whilst also earning a PhD in Engineering, attending Imperial College Business School and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers.
We enable earlier detection and more effective treatment of cancer worldwide. Those whose lives have been impacted by our work continue to remind me of the tremendous importance of the work the Oncimmune team does every day.
Dr Adam M Hill
Chief Financial Officer
Matthew is a seasoned finance professional with over 25 years of corporate finance experience in a number of leading organisations and fast-growing companies. Matthew is a Chartered Accountant who initially spent 20 years as an investment banker with a focus on M&A as well as equity and debt funding for fast growing companies.
Over the past 10 years, Matthew has undertaken Chief Financial Officer roles for a number of life science companies, including, most recently CFO for Tusk Therapeutics, who was successfully divested for c.€650 million to Roche. Previously, Matthew was CFO at Sphere Medical Holding plc where he was appointed to lead the company’s successful IPO and prior to that was CFO of IS Pharma plc, where he was closely involved in the merger of IS Pharma plc and Sinclair Pharma plc.
We’re at one of the most exciting times in Oncimmune’s history as we partner with leading biopharmaceutical and diagnostic companies around the world to make our products and immune expertise available for earlier detection and improved treatments of cancer.
Chief Business Officer
After 20 years in the life sciences industry, Cameron has a unique combination of technical and global commercial experience having served in a range of executive roles for Fortune 500 companies and high growth new ventures across the life sciences research, tools, biomarker development and molecular diagnostics sectors. Cameron started his career in clinical and preclinical imaging R&D, spending 10 years with Agilent Technologies where, as the VP/GM of the laboratory enterprise division, he led the creation of the company’s global strategic account program. More recently, Cameron was the VP/GM of IDEXX Laboratories global bio analytics division (reference laboratories).
Cameron holds degrees in business and engineering technology, information systems and an MBA from the London School of Business. Natively from New Zealand and now based in Boston, USA, Cameron has extensive global experience having lived and worked in Germany, Ireland, Netherlands, Australia, and the UK.
Oncimmune is at an incredibly exciting time of its evolution; our technology continues to unlock value for pharmaceutical and academia partners, providing otherwise unobtainable insights across the drug discovery continuum and supporting these partners to advance the human condition through faster and safer pharmaceutical discovery.
General Counsel and Company Secretary
Ron is a qualified lawyer with over 18 years of experience in advising international companies, including those in the bio-technology and healthcare sector. Ron began his career in the corporate team of Allen & Overy, in its London, Hong Kong and Bangkok offices, before moving to Baker & McKenzie, the international law firm. Ron has also held senior in-house positions, including in Barclays Bank and Genus Plc, where he was interim General Counsel over a 12 month period.
Most recently Ron was Senior Counsel at Smith & Nephew plc, the London-listed global medical devices company, where he led the legal team supporting the European commercial operations. Ron was a member of Smith & Nephew’s UK management team and took part in its European leadership team.
Ron has extensive international experience, having spent several years working in Asia and regularly advising on international transactions.
Ron graduated from the University of Birmingham with an LLB in Law & Business Studies. He is admitted to practice law in England and Wales.
Whatever our roles are at Oncimmune, enabling cancer to be diagnosed earlier and for people to have extra time is what we work towards every day.